Mirror Biologics Revenue
Biotechnology Research • 
Wesley Chapel, Florida, United States • 11-20 Employees
Mirror Biologics revenue & valuation
| Annual revenue | $1,711,100 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $5,500,000 |
| Total funding | No funding |
Key Contact at Mirror Biologics
Frank Gary Renshaw
Senior Medical Director
Company overview
| Headquarters | 2818 Cypress Ridge Blvd, Suite 110, Wesley Chapel, Florida 33544, US |
| Website | |
| NAICS | 541714 |
| Keywords | Healthcare, Pharma, bio |
| Founded | 2019 |
| Employees | 11-20 |
| Socials |
Mirror Biologics Email Formats
Mirror Biologics uses 3 email formats. The most common is {first name} (e.g., john@mirrorbio.com), used 61.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@mirrorbio.com | 61.1% |
{first initial} | j@mirrorbio.com | 33.3% |
{last name} | doe@mirrorbio.com | 5.6% |
About Mirror Biologics
Mirror Biologics is an international biopharmaceutical company headquartered in Tampa, Florida with operations in Jerusalem, Israel, Kuala Lumpur, Malaysia and Bangkok, Thailand. We are developing “off-the-shelf”, non-genetically manipulated, living immune cell therapies for metastatic solid tumors and as universal vaccine against respiratory viral infection in the elderly. In Tampa, we operate a 21 CFR 1271 registered blood donor center and conduct advanced bioreactor research and prototype development for commercial cell therapy manufacturing and also operate a clinical immunology lab for analysis of clinical samples. In Jerusalem we operate a GMP cell manufacturing and research facility. We also have clinical support and cold chain distribution operations in Bangkok, Thailand and Kuala Lumpur, Malaysia. The Mirror Effect technology platform enables reverse engineering of known effective immune responses and imprinting of these immune cascades upon failed immune systems. Mirror Effect technology is protected by over 200 patents issued worldwide. The lead drug, AlloStim®, is a patented, disease-agnostic, allogeneic living immune cell differentiated from precursor cells purified from blood of healthy donors and formulated with monoclonal antibody-coated microparticles. The unique feature of AlloStim® is that can imprint a protective or therapeutic cellular immune response that is customized to a patient’s resident disease without the need to have prior knowledge of the type of cancer/virus or genetic properties/antigenic structure of the disease. Proprietary “artificial lymph node” bioreactors are under development which are designed for high volume, high density scale-up of AlloStim®. Novel frozen dosage forms enable extended shelf life and economical distribution. Mirror Biologics purchased the exclusive, worldwide rights to AlloStim® and the Mirror Effect technology platform from Immunovative Therapies, Ltd, an Israeli company.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Mirror Biologics has 9 employees across 5 departments.
Departments
Number of employees
Funding Data
Mirror Biologics has never raised funding before.
Mirror Biologics Tech Stack
Discover the technologies and tools that power Mirror Biologics's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Issue trackers
Appointment scheduling
JavaScript libraries
Blogs
Miscellaneous
Security
Miscellaneous
JavaScript frameworks
IaaS
CDN
United Arab Emirates
Frequently asked questions
4.8
40,000 users
